GIANT BIOGENE

2367
20.1402.34% ( +0.460 )
Delay Closed: Nov 16, 16:08:11

Overview

GIANT BIOGENE (2367)

Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty a...

Open
19.620
High
20.160
Low
19.560
Prev. Close
19.680
Volume
2.43M
Turnover
48.55M
Avg Price
19.976
Bid/Ask Ratio
-64.71%
Amplitude
3.05%
52wk High
39.931
Volume Ratio
0.46
Turnover Ratio
0.23%
52wk Low
19.340
HK Mkt Cap
21.38B
Market CapHKD
21.38B
P/ETTM
11.10
P/EDynamic
9.88
P/EStatic
--
EPSTTM
1.81
EPSDynamic
2.04
EPSStatic
--
BVPS
10.15
P/B
1.98
HK Shares
1.06B
Dividend YieldTTM
6.90%
DividendTTM
1.3894
Shares
1.06B
Min lot size
200
Currency
HKD

GIANT BIOGENE Analyst Rating

View more

Forecast & Rating

Nov 9, 2026
Price forecast
HK$36.4981.17%
Forecast & RatingBuy
16analysts
  • Strong buy68.75%
  • Buy6.25%
  • Hold18.75%
  • Sell6.25%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Giant Biogene advanced 2.3% today to close at HK$20.14, with the morning session opening at HK$19.95 before consolidating, while afternoon trading gathered momentum to reach an intraday peak of HK$20.16. The rebound is underpinned by two factors. First, the stock has retreated 41% year-to-date and now trades 51% below its 52-week high of HK$41.32, hovering just 4% above the October low of HK$19.34, signaling that valuations have compressed significantly. At 11.1x P/E and 1.98x P/B with a dividend yield of 6.9%, the stock appears reasonably valued for Hong Kong equities. Second, despite earnings per share declining 16-17% year-over-year in the recent two quarters, operating revenue has remained broadly stable and net profit margins held steady at 32%, with most brokers maintaining 'buy' ratings and citing differentiated product pipelines and scalable innovation. However, the stock still trades below both its 20-day moving average of HK$20.69 and 60-day average of HK$23.49, while headwinds from decelerating online cosmetics growth in China and intensifying domestic brand competition continue to weigh on investor sentiment, warranting caution on near-term catalysts.

  2. Nov, 13

    Giant Biogene's Hong Kong shares declined 3.85% to close at HK$19.68, pressured by weakening demand and intensifying competition in the cosmetics sector. Intraday weakness persisted despite early strength—the stock peaked at HK$20.26 in the morning but retreated to HK$19.67 by afternoon close, reflecting sustained selling pressure. Recent earnings underscore the headwinds: net profit fell 16.47% and 16.98% year-over-year in Q1 and Q2 2026 respectively, while Q2 revenue slipped 1.19% year-on-year despite stable sequential performance, signaling a slowdown in China's online cosmetics sales and heightened domestic brand competition. Valuation metrics remain supportive with a P/E of 10.85x, P/B of 1.94x, and a dividend yield of 7.06%. However, the price action tells a cautionary story: shares have tumbled 42.49% year-to-date and now trade 52.37% below the 52-week high of HK$41.32, hovering near the 52-week low of HK$19.34, suggesting market concerns about growth recovery are largely priced in.

  3. Nov, 12

    Giant Biogene slid roughly 4% intraday today, with losses concentrated in afternoon trading, weighed by mounting concerns over cosmetics sector demand fundamentals. Citi's latest research highlighted that China's online cosmetics sales growth decelerated notably in Q3 2026, with homegrown brands outperforming, creating headwinds for niche segments like Giant Biogene's positioning. Q2 earnings underscore the pressure—while revenues held roughly flat (down 1.19% year-over-year), net profit and EPS both contracted roughly 16%, reflecting margin compression from rising costs and intensifying competition. Positionally, the stock has fallen about 40% year-to-date and over 50% from its December 2025 peak of HKD 41.32, yet the current valuation remains compressed at just 11.28x P/E. Notably, a robust 6.79% dividend yield coupled with stable 32% net profit margins continue to underpin fundamentals, with analysts crediting the combination of attractive valuation and consistent dividend support.

  4. Nov, 11

    Giant Biogene shares rose 1.91% to HK$21.30 today, with the afternoon session driving the gains after opening at HK$21.06 at 13:00 BJ, reaching the session high of HK$21.30 by market close at 16:00. The rebound was supported by analyst affirmation of buy ratings, emphasizing the company's differentiated product pipeline, scalable innovation capabilities, and attractive valuation with strong dividend support. On the fundamental front, Q1-Q2 revenues remained relatively stable with modest year-over-year declines of only 0.6-1.2%, though net profit contracted roughly 16%, reflecting margin compression amid competitive pressures. The valuation remains compelling at just 11.74x PE and 2.10x PB. However, the stock has tumbled 37.76% year-to-date from an initial price of HK$34.22, trading near 52-week lows (down 48.45% from the HK$41.32 peak), as China's online consumer demand growth slows and the broader beauty and wellness retail sector faces headwinds.

  5. Nov, 10

    Giant Biogene gained approximately 2.5% to close at HK$20.90, hitting an intraday high of HK$20.98, buoyed by analyst endorsements highlighting differentiated product pipelines, scalable innovation, and attractive valuations with strong dividend support at 6.65%. While recent quarters show earnings pressure with Q2 EPS declining 16.98% year-over-year to HK$0.514, revenue remains relatively stable at HK$16.85 billion with just a -1.19% YoY decline, sustaining a robust net margin of 32% and ROE near 20%. From a valuation perspective, the stock has fallen 38.92% year-to-date and now trades merely 8% above its 52-week low of HK$19.34 reached in late October, positioning it near historical bottom; with a PE ratio of 11.52, the valuation represents a relative low point that likely underpins institutional buying interest.

News

Bullish vs. Bearish — Last 3 Months

6.5k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • P
    Profit

    The Hong Kong stock market is now a tale of two extremes. Mixue Group is exploding directly, this wave of beverages really gives a bull market feeling. However, cyclical stocks like oil services, such as BQE Petroleum Services, fell nearly 10% in a single day, not even enough time to cut losses.

    Those two in new energy and biotech (Goldwind Science & Technology, Giant Biogene), seem to have no presence, just floating along passively.

    RoboSense pulled up a bit, the smart vehicle track still has some popularity.

    Now, we can only watch and choose, continue to endure...

  • M
    momoM

    $MAO GEPING(01318.HK) feels like it's not that hot, will check the excess multiple later $GIANT BIOGENE(02367.HK)

    图片 1,共 1 张